This page shows the latest Protelos news and features for those working in and with pharma, biotech and healthcare.
Both drugs were originally rejected earlier this year. It also reported that Servier had elected to withdraw its application to extend the indications of its osteoporosis therapy Protelos/Osser (strontium ranelate)
That review brought restrictions that included a prohibition on the use of Protelos' in immobilised patients or patients with a history of venous thromboembolism (VTE). ... This time around the PRAC wants the EMA's Committee for Medicinal Products for
Servier Laboratories, the licence holder of Protelos (strontium ranelate), which instigated the review, remains satisfied with Mr Holman's judgement that NICE acted with procedural unfairness, and therefore unlawfully, by not
The High Court has ruled that NICE must look again at its decision not to fund the use of osteoporosis drug Protelos on the NHS. ... The High Court has ruled that the National Institute for Health and Clinical Excellence (NICE) must look again at its
Protelos shines in study. Servier's osteoporosis treatment, Protelos, is effective in reducing nonvertebral and vertebral fractures over five years, according to two new studies presented at the Sixth European Congress ... One trial of 1649
Protelos - for osteoporosis. As a passionate believer in the relevant unexpected, I suppose this ad is totally relevant in its visual context but not entirely unexpected - unless one expects to see
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...